This article is more than 5 years old. Information may no longer be current.

Imprimis’ MKO Melt receives patent

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Imprimis has received a patent for its MKO Melt compounded formulation from the U.S. Patent and Trademark Office, according to a press release.

The MKO Melt (midazolam, ketamine and ondansetron) is a nonopioid, IV-free sublingual formulation for sedation.

“We are pleased to have been granted this patent which covers our MKO Melt formulation and a variety of other versions of midazolam and ketamine combinations we intend to make available to address unmet patient needs,” Mark L. Baum, Imprimis CEO, said in the release.

The MKO Melt has been used in more than 10,000 cataract surgeries and could be of benefit in a wide range of surgical procedures beyond cataract surgery, according to the release.

Publication of results are pending for a prospective, randomized, double-masked, investigator-initiated study of 724 patients undergoing cataract surgery, and a prospective, randomized, double-masked study of cataract surgery patient comfort associated with anesthesia is underway.